Table 5

Comparisons of area under curves (AUCs) between patients with composite complication ≤3 and >3, respectively, based on two-sample t-test

Parameters and thresholdsComposite complication ≤3
(n=70)
Composite complication >3
(n=32)
P value
AUC  >0 (n)AUC median (Q1–Q3) (unit*min)AUC >0 (n)AUC median (Q1–Q3) (unit*min)
MAP <50 mm Hg2012 (1–30)1727 (10–53)0.3
MAP <60 mm Hg3529 (7–60)2643 (9–142)0.2
MAP <70 mm Hg54110 (50–331)31254 (94–441)0.08
MAP >100 mm Hg60157 (40–373)30482 (152–714)0.045
MAP >110 mm Hg49109 (48–206)28241 (88–504)0.05
MAP >120 mm Hg4382 (34–150)26174 (52–338)0.04
Temp <35°C2128 (6–79)2336 (16–77)0.4
Temp <35.5°C4435 (9–90)26113 (52–172)0.057
Temp <36°C5797 (44–146)28217 (88–305)0.008
Temp >37°C2024 (6–52)923 (7–37)1.0
Temp >37.5°C69 (4–30)23 (1–5)0.3
Temp >38°C1NA0NANA
SpO<90%723 (2–53)3928 (32–6561)0.08
SpO<95%1116 (1–45)541 (23–1255)0.08
HR <40 bpm0NA21452 (1–2904)NA
HR <50 bpm1619 (1–58)8209 (16–521)0.09
HR <60 bpm33360 (46–1000)20161 (21–1966)0.1
HR >90 bpm16234 (81–426)7350 (84–860)0.9
HR >100 bpm1390 (20–146)5164 (75–215)0.8
HR >110 bpm1051 (15–77)426 (8–42)0.3
PI <0.5277 (1–21)134 (0.3–15)1.0
PI <14730 (4–101)1828 (7–72)0.8
PI >6152 (0.3–10)1026 (1–210)0.03
PI >100NA397 (0.2–217)NA
iVt <5 mL/kg69447 (340–565)32606 (432–751)0.007
iVt <6 mL/kg69689 (581–860)32986 (725–1168)0.004
iVt >8 mL/kg1NA0NANA
iVt >9 mL/kg1NA0NANA
iVt >10 mL/kg0NA0NANA
aVt <5 mL/kg528 (3–44)2718 (5–107)0.2
aVt <6 mL/kg64107 (11–296)3078 (11–335)0.4
aVt >8 mL/kg202 (1–13)121 (1–11)0.5
aVt >9 mL/kg121 (0.1–10)70.3 (0.1–7)1.0
aVt >10 mL/kg71 (0.03–23)41 (0.02–31)0.8
Ppeak <10 cmH2O284 (2–9)188 (3–22)0.3
Ppeak <15 cmH2O4614 (5–55)2229 (7–59)0.049
Ppeak >25 cmH2O2412 (2–153)876 (7–177)0.8
Ppeak >30 cmH2O824 (2–89)423 (5–71)0.6
Ppeak >35 cmH2O220 (18–22)25 (2–8)0.05
PEEP <3 cmH2O334 (1–57)203 (1–9)0.5
PEEP >7 cmH2O1412 (2–59)349 (2–295)0.4
PEEP >10 cmH2O52 (1–9)1NANA
EtCO>25 mm Hg2616 (8–30)1311 (8–27)0.3
EtCO>30 mm Hg3922 (5–45)2315 (7–69)0.3
EtCO>40 mm Hg4458 (15–208)1958 (11–339)1.0
EtCO>45 mm Hg2329 (5–198)1125 (3–153)0.4
FiO2  <0.354124 (2–884)21272 (11–2532)0.4
FiO<0.451299 (59–190)967 (36–223)0.9
FiO>0.75651183 (248–4216)311395 (672–3336)0.9
FiO>0.8558521 (111–2698)28672 (317–1851)0.7
SctO<50%3152 (74–213)374 (17–3643)0.4
SctO<55%6136 (12–481)721 (8–232)0.6
SctO2 <60%1572 (8–331)12112 (40–345)0.8
SctO>75%48135 (5–248)20155 (55–515)0.5
SctO>80%2521 (6–58)1211 (2–96)0.7
SctO>85%531 (0.3–40)325 (11–93)0.9
SctO>90%1NA1NANA
SstO<50%10368 (1–1664)686 (15–100)0.4
SstO<55%14113 (23–2328)8130 (17–394)0.4
SstO<60%22116 (23–1388)1064 (18–954)0.4
SstO>75%56874 (203–1827)311419 (283–2382)0.1
SstO>80%44316 (93–1069)27523 (103–1071)0.4
SstO>85%26162 (13–543)19125 (20–463)0.6
SstO>90%510 (4–17)412 (3–25)0.6
  • Only patients whose AUCs were >0 were included in analysis.

  • NA, not assessable; Q1,  first quantile; Q3,  third quantile.